BRD2 and glaucoma: The anti-glaucoma formulations of the current study were designed to (a) control the delivery of 5-MCA-NAT, thus prolonging the hypotensive effect, and (b) replenish the tear film, which may improve an ocular surface damaged by chronic exposure to topical treatments.